Sarepta Therapeutics | SRPT - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 243.27M 14.49M 2026-03
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amgen USD 6.89B 415M 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Biogen USD 1.82B 169.5M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Capricor Therapeutics 11.13M 8.87M 2024-12
Daiichi Sankyo JPY 439.83B 95.05B 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Gilead Sciences USD 5.52B 791M 2026-03
Incyte USD 1.17B 217.51M 2026-03
Insmed USD 256.46M 38.78M 2026-03
Ionis Pharmaceuticals USD 243M 48M 2026-03
Moderna USD -566M 792M 2026-03
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novavax USD 125.04M 76.09M 2025-12
Pfizer USD 11.04B 1.24B 2026-03
PTC Therapeutics USD 232.94M 84.56M 2026-03
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.45B 1.31B 2025-12
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
Tectonic Therapeutic USD 0 0 2025-03
Ultragenyx Pharmaceutical USD 106M 72M 2026-03
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03